ZARZA We are Zarza, the prestigious firm behind major projects in information technology.

BiotechTV - News

Por: BiotechTV

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

343 episodios disponibles

Latest episodes of the podcast BiotechTV - News

Mostrando página 3 de 18

Jefferies London: Jefferies M&A Banker Chris Roop shares his take on the environment for deals in biotech 17/11/2025

Legend Biotech CEO Ying Huang shares a post-earnings update from the company's new R&D Center in Philadelphia 13/11/2025

Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP. 12/11/2025

Avalo Therapeutics is developing a high affinity IL-1β for hidradenitis suppurativa - key phase 2 data will come next year 12/11/2025

Stifel's Head of Global Equity Capital Markets Seth Rubin describes the investor feedback he is hearing about the sector lately and the fundraising environment for companies 12/11/2025

Sionna Therapeutics is trying to improve the treatment paradigm for cystic fibrosis by targeting NBD1, a nucleotide binding-domain of the CFTR protein, and restore healthy function for all 12/11/2025

Stifel's I&I expert Alex Thompson shares his take on the environment and discusses names he covers that have key catalyst events 12/11/2025

Celcuity release what it believes is practice changing breast cancer data with its multi-target PAM inhibitor. Co-Founder & CEO Brian Sullivan describes why he believes the data is so important 11/11/2025

Spyre Therapeutics is developing a basket of therapies (α4β7, TL1A, and IL-23) that are meant to have a greater half-life and work better in combination that current therapies for IBD and rheumatology 11/11/2025

Vicore Pharma is leveraging in understanding the Renin-Angiotensin System (RAS) to develop angiotensin II type 2 receptor agonists for IPF and beyond 11/11/2025

The early part of 2026 is going to be a key time for REGENXBIO's gene therapies, with an FDA decision date schedule for Hunter's Syndrome and a pivotal trial readout in DMD 11/11/2025

Aardvark Therapeutics' approach to obesity is to inhibit hunger (vs appetite). It has a key pivotal trial scheduled to read in Prader-Willi syndrome early next year, and is also working on weight loss 11/11/2025

Stifel's Head of Therapeutics Paul Matteis shares his take on the sector and discusses names he covers that have key catalyst events 11/11/2025

Upstream Bio is focused on the TSLP space, and has a unique approach of targeting the receptor as opposed to the ligand. It might give them a better dosing and efficacy profile. 11/11/2025

Adaptyx announced $14M in additional seed financing to fund the development of a continuous health monitoring device that aims to track small molecules, electrolytes, hormones, drugs, and proteins 10/11/2025

Aulos Bioscience presented phase 2 data at SITC for its antibody that binds to IL-2 and prevents CD25 binding - showing responses in melanoma and lung 08/11/2025

Enara Bio publicly announced its first cancer specific 'dark genome antigen' target at SITC - DARKFOX, an alternative open reading frame associated with FOXM1 08/11/2025

Compugen is standing firm on its belief that TIGIT will ultimately succeed with Fc reduced/silent constructs 08/11/2025

Synthekine presented data at SITC on its α/β-IL-2 receptor biased partial agonist showing a 53% response rate in PD-L1 negative nonsquamous NSCLC 08/11/2025

Marengo Therapeutics has presented data at ESMO and SITC showing that its lead program, which is designed to activate Vβ6/10 T cells, is active in multiple tumor types 08/11/2025

« Primera ‹ Anterior 1 2 3 4 5 ... 18 Siguiente › Última »